<DOC>
	<DOCNO>NCT00069849</DOCNO>
	<brief_summary>The purpose study compare safety efficacy 2 mg , 4 mg , 20 mg ABT-089 BID placebo adult Alzheimer 's disease .</brief_summary>
	<brief_title>A Study Safety Efficacy Multiple Doses ABT-089 Subjects With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>INCLUSION CRITERIA : Current diagnosis probable Alzheimer 's disease . ADAScog score least 12 MMSE score 10 26 . Nonsmoker Must legally authorize representative reliable caregiver . The caregiver legally authorize representative may person . Fluent English . EXCLUSION CRITERIA : Use cholinesterase inhibitor drug treat Alzheimer 's disease last 6 week . Has clinically significant uncontrolled medical condition Alzheimer 's disease . Nursing home resident .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>